An observational study in Plasmodium Falciparum, sponsored by University of Oxford. Completed at 1 site in Chad. Open to participants aged 6 Months to 75 Years. Per ClinicalTrials.gov, last updated 2022-04-07.
Sponsored by University of Oxford · Observational
This study is to measure prevalence of established and candidate molecular markers of drug resistant malaria at Komé, Doba, Republic of Chad.
This is a cross-sectional, observational study using dried blood samples collected from P. falciparum-infected individuals at the time of malaria diagnosis to measure the prevalence of known and candidate molecular markers of resistance to artemisinin and non-artemisinin ACT partner drugs. A maximum of 200 participants will be enrolled at each participating site per year. Study duration is 2 years. Therefore total participant is up to 400.
Prospective participants will have blood collected for dried blood spot (DBS) study sample after providing informed consent. Individuals with confirmed P. falciparum infection will have DBS samples included for molecular analyses for known and candidate molecular markers of antimalarial drug resistance.
1,299 studies on the registry are indexed under Malaria; 86 are open to participants now.
This study's enrollment of 399 is below the median of 600 across 218 observational studies indexed under Malaria.
Browse Malaria studies →University of Oxford is the lead sponsor of 794 studies on the registry; 117 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Study participants will be the patients presenting at study clinics with signs and symptoms of malaria (including but not limited to headache, body aches, fever, chills, and weakness) and confirmed P. falciparum infection.
Participants must meet all of the inclusion criteria to participate in the study.
Exclusion Criteria:
Percent prevalence of kelch13 mutants (marker of resistance to artemisinins)
Time frame: 2 years
Percent prevalence of specimens with pfmdr1 copy number >1 (marker of resistance to mefloquine)
Time frame: 2 years
Visualization and dissemination of molecular marker prevalence data to inform public health officials, researchers, policymakers and key stakeholders
Time frame: 2 yeas
Plan to share: Undecided
This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Oxford